Mobile

A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s d...

Mise à jour : Il y a 4 ans
Référence : U1111-1116-2695

A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the trial is to compare disease activity following a single s.c. dose of NNC142-0002 to placebo in subjects with moderately to severely active CD, measured 4 weeks after administration.

Critère d'inclusion

  • Crohn’s Disease

Liens